Study S000778

A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT05433584
Acronym: SURPASS-EARLY
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 780
Start: 2022-08-01
Primary completion: 2025-10-21
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes
Interventions: DRUG:Tirzepatide; DRUG:Antihyperglycemic medication
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPHE; EUDRACT_NUMBER:2022-000130-42; OTHER:2022-5010733-40-00; REGISTRY:U1111-1282-0263

Registered primary outcomes

Change from Baseline in Hemoglobin A1c (HbA1c) [Baseline, Week 104]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002665	Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial. Del Prato S, Annals of internal medicine	2026	Randomized trial	PMID 42184419 DOI	cites ClinicalTrials.gov:NCT05433584; registry reference DERIVED:42184419